These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2018441)

  • 1. Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency.
    McMullin GM; Watkin GT; Coleridge Smith PD; Scurr JH
    Aust N Z J Surg; 1991 Apr; 61(4):306-9. PubMed ID: 2018441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression.
    Burnand K; Clemenson G; Morland M; Jarrett PE; Browse NL
    Br Med J; 1980 Jan; 280(6206):7-11. PubMed ID: 6986945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial.
    Carson P; Hong CJ; Otero-Vinas M; Arsenault EF; Falanga V
    Int J Low Extrem Wounds; 2015 Mar; 14(1):11-8. PubMed ID: 25652757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute lipodermatosclerosis: an open clinical trial of stanozolol in patients unable to sustain compression therapy.
    Vesić S; Vuković J; Medenica LJ; Pavlović MD
    Dermatol Online J; 2008 Feb; 14(2):1. PubMed ID: 18700104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pericapillary fibrin deposits and skin hypoxia precede the changes of lipodermatosclerosis in limbs at increased risk of developing a venous ulcer.
    Stacey MC; Burnand KG; Bhogal BS; Black MM
    Cardiovasc Surg; 2000 Aug; 8(5):372-80. PubMed ID: 10959062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy using stanozolol and measurement of transcutaneous oxygen].
    Neumann HA; vd Broek MJ
    Phlebologie; 1988; 41(3):679-82. PubMed ID: 3222316
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical spectrum of lipodermatosclerosis.
    Kirsner RS; Pardes JB; Eaglstein WH; Falanga V
    J Am Acad Dermatol; 1993 Apr; 28(4):623-7. PubMed ID: 8463465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Raynaud's phenomenon by fibrinolytic enhancement.
    Jarrett PE; Morland M; Browse NL
    Br Med J; 1978 Aug; 2(6136):523-5. PubMed ID: 698554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol.
    Belch JJ; Madhok R; McArdle B; McLaughlin K; Kluft C; Forbes CD; Sturrock RD
    Q J Med; 1986 Jan; 58(225):19-27. PubMed ID: 3517926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement.
    Jarrett PE; Morland M; Browse NL
    Br Med J; 1977 Apr; 1(6066):933-4. PubMed ID: 856391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis.
    Jayson MI; Holland CD; Keegan A; Illingworth K; Taylor L
    Ann Rheum Dis; 1991 Jan; 50(1):41-7. PubMed ID: 1994867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pericapillary fibrin cuffs in venous ulceration. Persistence with treatment and during ulcer healing.
    Falanga V; Kirsner R; Katz MH; Gould E; Eaglstein WH; McFalls S
    J Dermatol Surg Oncol; 1992 May; 18(5):409-14. PubMed ID: 1607464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lipodermatosclerosis with oxandrolone in a patient with stanozolol-induced hepatotoxicity.
    Segal S; Cooper J; Bolognia J
    J Am Acad Dermatol; 2000 Sep; 43(3):558-9. PubMed ID: 10954677
    [No Abstract]   [Full Text] [Related]  

  • 14. Fibrinolytic enhancement by stanozolol: a double blind trial.
    Davidson JF; Lochhead M; McDonald GA; McNicol GP
    Br J Haematol; 1972 May; 22(5):543-59. PubMed ID: 4555715
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and laboratory double-blind investigation on effect of fibrinolytic therapy in patients with cutaneous vasculitis.
    Dodman B; Cunliffe WJ; Roberts BE; Sibbald R
    Br Med J; 1973 Apr; 2(5858):82-4. PubMed ID: 4573315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind randomized trial of perioperative fibrinolytic enhancement for femoropopliteal bypass.
    Berridge DC; Frier M; Westby JC; Hopkinson BR; Makin GS
    Br J Surg; 1991 Jan; 78(1):101-4. PubMed ID: 1998848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic enhancement with stanozolol fails to improve symptoms and signs in patients with post-surgical back pain.
    Cooper RG; Mitchell WS; Illingworth KJ; Jayson MI
    Scand J Rheumatol; 1991; 20(6):414-8. PubMed ID: 1837614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stanozolol as a novel therapeutic agent in dermatology.
    Helfman T; Falanga V
    J Am Acad Dermatol; 1995 Aug; 33(2 Pt 1):254-8. PubMed ID: 7622653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of fibrinolytic stimulation by stanozolol on postoperative pulmonary complications.
    Cuschieri RJ; Morran CG; Lowe GD; Blamey SL; Forbes CD; McArdle CS
    Haemostasis; 1985; 15(5):353-6. PubMed ID: 4076841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis of skin pathologic changes and ulceration].
    Qian HS
    Zhonghua Yi Xue Za Zhi; 1993 Jun; 73(6):352-4, 381-2. PubMed ID: 8258106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.